Loading...
Observational studies suggest that denosumab (Prolia), a biologic RANK ligand inhibitor used as an antiresorptive agent to treat patients with osteoporosis, might have beneficial effects on glucose metabolism. Researchers used a British primary care database to identify 4300 patients with osteoporosis and without diabetes who started using denosumab (either as a first agent or after switching from a bisphosphonate) between 2010 and 2021. Each denosumab recipient was matched to as many as 5 similar bisphosphonate recipients, with appropriate adjustment for differences between groups.
During 5 years of follow-up, denosumab users were significantly less likely than bisphosphonate users to develop type 2 diabetes (5.7 vs. 8.3 per 1000 person-yea…